Cellectis Stock Soars 12% Midday After Nature Publication
The stock of French biotech company Cellectis has risen by 12.06% at mid-session this Monday, November 24, trading at 4.60 euros. This surge is part of a remarkable upward trend, with the stock having gained 35.1% over the week and more than doubled since the start of the year.
Scientific Breakthrough Published in Nature Communications
Cellectis published a scientific article on Tuesday, November 19, in Nature Communications, demonstrating that single-strand circular DNA (CssDNA) serves as an effective non-viral DNA matrix for gene insertion in hematopoietic stem cells. The CssDNA method shows a gene insertion efficiency 3 to 5 times higher than that of single-strand linear DNA, with insertion rates exceeding 40%. This major technological advance opens new prospects for non-viral gene therapies, a field in which the Paris-based company holds recognized expertise. The stock began its rise on Wednesday, November 20, the day after the publication, and continues its ascent this Monday in a slightly declining Paris market by 0.14%. Technically, the stock is now well above its 50-day moving average, established at 3.21 euros, confirming the strength of the bullish movement that started several weeks ago. The RSI is at 77, indicating a pronounced overbought situation that traditionally calls for caution. The stock has crossed its resistance threshold of 4.30 euros identified by analysts and displays a high volatility of 24.22% over a month, characteristic of the biotechnology sector in the clinical phase.
Remarkable Quarterly Performance
The stock's quarterly performance has been spectacular, with a jump of 83.27% over three months and 166.5% over a year, far outpacing the CAC 40 which has risen by 9.88% over the same period. The trading volumes this Monday remain moderate with 0.84% of the capital traded, suggesting a rise driven more by enthusiasm for scientific advances than by massive speculative movements. Beyond this scientific publication, Cellectis had a consolidated cash reserve of 225 million dollars as of September 30, 2025, ensuring financial visibility until the second half of 2027. The company also announced that it would present new clinical data on its eti-cel program at the annual congress of the American Society of Hematology (ASH) to be held from December 6 to 9 in Orlando. These scientific meetings are potential catalysts for the stock in the coming weeks.
Favorable Recent Context for Cellectis
The recent context remains generally favorable for Cellectis. The company presented encouraging results at the beginning of November for its candidate lasme-cel with an overall response rate of 68% in Phase 1, reaching 83% at the recommended dose for Phase 2 and 100% in the target population of Phase 2. These clinical advances fuel investor interest in this biotech specialized in genome editing, although the current valuation already reflects high expectations. The positive MACD histogram at 0.12 confirms the short-term bullish momentum, while the upper Bollinger band at 4.11 euros has just been crossed, signaling an extension of the movement. The coming weeks will be crucial to confirm whether or not the stock can consolidate its recent gains, in a context where technical indicators suggest a marked overbought phase.
